Endocrine Abstracts

Background: Alpelisib is an α-selective PI3K inhibitor indicated for the treatment of postmenopausal women and men with hormone receptor-positive (HR+), human epidermal growth receptor 2-negative (HER2–), PIK3CA-mutated locally advanced or metastatic breast cancer following disease progression or after endocrine therapy. Hyperglycemia is the most common adverse event (up to 60%) associated with its use. It occurs more frequently and lasts longer in patients with pred...